STOCK TITAN

Niagen Bioscience (NAGE) CEO adds 20,000 shares via option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Niagen Bioscience Chief Executive Officer Robert N. Fried exercised stock options to acquire 20,000 shares of Common Stock at an exercise price of $2.61 per share. He paid the exercise price in cash and, according to the footnotes, has not sold any of the shares received.

Following the exercise, Fried directly holds 1,058,981 shares of Common Stock. He also reports indirect holdings through family-related accounts and trusts, including 12,746 shares held by his sons and additional shares held in separate irrevocable and revocable trusts, while disclaiming beneficial ownership of those indirect securities.

Positive

  • None.

Negative

  • None.
Insider Fried Robert N
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Stock Options (right to buy) 20,000 $0.00 --
Exercise Common Stock 20,000 $2.61 $52K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Options (right to buy) — 0 shares (Direct, null); Common Stock — 1,058,981 shares (Direct, null); Common Stock — 95,001 shares (Indirect, By Fried-Travis Revocable Trust U/A Dated 06/02/1999)
Footnotes (1)
  1. The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.
Options exercised 20,000 shares Stock options exercised by CEO on 2026-04-24
Exercise price $2.61 per share Cash exercise of stock options
Direct holdings after exercise 1,058,981 shares Common Stock directly held by CEO after transaction
Sons’ combined holdings 12,746 shares Common Stock held by Jeremy and Benjamin Fried
Benjamin trust holdings 250,000 shares Common Stock held by Benjamin A. Fried 2020 Irrevocable Trust
Jeremy trust holdings 250,000 shares Common Stock held by Jeremy W. Fried 2020 Irrevocable Trust
Revocable trust holdings 95,001 shares Common Stock held by Fried-Travis Revocable Trust
Exercised grant expiration November 15, 2026 Original expiration date of exercised stock options
stock options financial
"The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
irrevocable trust financial
"Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020"
revocable trust financial
"By Fried-Travis Revocable Trust U/A Dated 06/02/1999"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fried Robert N

(Last)(First)(Middle)
10900 WILSHIRE BLVD. SUITE 600

(Street)
LOS ANGELES CALIFORNIA 90024

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/24/2026M20,000A$2.61(1)1,058,981D
Common Stock95,001IBy Fried-Travis Revocable Trust U/A Dated 06/02/1999
Common Stock250,000IBy US Trust Co. of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020(2)
Common Stock250,000IBy US Trust Co. of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020(2)
Common Stock12,746ISee Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (right to buy)$2.6104/24/2026M20,00011/16/201711/15/2026Common Stock20,000$00D
Explanation of Responses:
1. The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise.
2. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
3. 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.
Remarks:
/s/ Jeong James Lee, Attorney-in-Fact04/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Niagen Bioscience (NAGE) report for its CEO?

Niagen Bioscience reported that CEO Robert N. Fried exercised stock options for 20,000 Common Stock shares. He paid the $2.61 per-share exercise price in cash and has not sold any of the shares received, indicating this was an exercise-and-hold transaction.

At what price did the Niagen (NAGE) CEO exercise his stock options?

Robert N. Fried exercised stock options at an exercise price of $2.61 per share. The options covered 20,000 shares of Common Stock, and a footnote states he paid the exercise price in cash rather than using a cashless method or selling shares.

How many Niagen Bioscience (NAGE) shares does the CEO hold after this Form 4?

After the reported transactions, CEO Robert N. Fried directly holds 1,058,981 shares of Niagen Bioscience Common Stock. This total reflects the addition of 20,000 shares obtained through option exercise, with no sales of those newly acquired shares disclosed.

Did the Niagen (NAGE) CEO sell any shares in this Form 4 filing?

No, the filing states that Robert N. Fried has not sold any of the shares received upon exercising his stock options. The transaction involved exercising options for 20,000 shares at $2.61 per share and holding all of the resulting Common Stock.

What happened to the stock options exercised by the Niagen (NAGE) CEO?

The 20,000 stock options exercised by Robert N. Fried, with a $2.61 exercise price and a November 15, 2026 expiration, are now fully converted. The derivative position is reduced to zero for that grant, and he holds the underlying 20,000 Common Stock shares directly.